Viswanathan SR, Ha G, Hoff AM, et al. Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing. Cell. 2018;174(2):433-447.e19. doi:10.1016/j.cell.2018.05.036
Schaub FX, Dhankani V, Berger AC, et al. Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas. Cell Syst. 2018;6(3):282-300.e2. doi:10.1016/j.cels.2018.03.003
Cho SW, Xu J, Sun R, et al. Promoter of lncRNA Gene PVT1 Is a Tumor-Suppressor DNA Boundary Element. Cell. 2018;173(6):1398-1412.e22. doi:10.1016/j.cell.2018.03.068
Margolin AA, Wang K, Califano A, Nemenman I. Multivariate dependence and genetic networks inference. IET Syst Biol. 2010;4(6):428-40. doi:10.1049/iet-syb.2010.0009
Benassi B, Flavin R, Marchionni L, et al. MYC is activated by USP2a-mediated modulation of microRNAs in prostate cancer. Cancer Discov. 2012;2(3):236-47. doi:10.1158/2159-8290.CD-11-0219
Brown JR, Hanna M, Tesar B, et al. Integrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at 8q24 in chronic lymphocytic leukemia. Clin Cancer Res. 2012;18(14):3791-802. doi:10.1158/1078-0432.CCR-11-2342
Chapuy B, McKeown MR, Lin CY, et al. Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. Cancer Cell. 2013;24(6):777-90. doi:10.1016/j.ccr.2013.11.003
Ichida JK, TCW J, Williams LA, et al. Notch inhibition allows oncogene-independent generation of iPS cells. Nat Chem Biol. 2014;10(8):632-639. doi:10.1038/nchembio.1552
McKeown MR, Bradner JE. Therapeutic strategies to inhibit MYC. Cold Spring Harb Perspect Med. 2014;4(10). doi:10.1101/cshperspect.a014266
Landau DA, Tausch E, Taylor-Weiner AN, et al. Mutations driving CLL and their evolution in progression and relapse. Nature. 2015;526(7574):525-30. doi:10.1038/nature15395